Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Azzak34on Sep 21, 2023 3:07pm
248 Views
Post# 35647962

Quentin30

Quentin30Everyone please read one of our bashers recent post. It may be the worst argument against Pela anyone has written and yet he continues to post his nonsense on a daily basis. 

1. He thinks the CR we had in our Panc trial was because the person ate something or experienced a placebo effect which cured his Pancreatic Cancer. 

2. He says we engage in too many unpowered trials yet we need more data to determine if our Panc results were any good. Despite PanCans selection of Pela. 

3. He says Pelas exclusivity to us will lapse in 2028 and we can add pixie dust to it. Does anyone have any? 

4. There is no institutional interest. Despite that $15 million an institutional healthcare investor just invested. 

5. We were granted approval for Phase 3 in MBC but the data was statistically insignificant.  Both things can't be true or we wouldn't have been approved for Phase 3. 

I can't say this often enough... He says the PR we had in Panc is because the person ate something or experienced a placebo effect!!! If this is your guy for info, you need to find a new guy. 
<< Previous
Bullboard Posts
Next >>